CAJ | 학술논문

目的：探讨新辅助化疗对三阴性乳腺癌（Triple Negative Breast Cancer，TNBC）患者核抗原Ki67的影响。方法选取2012年6月～2014年3月期间我院新辅助化疗治疗的 TNBC 患者136例，依据并采用免疫组化法检测所有患者乳腺癌组织中 Ki67表达情况，化疗前分为阳性组和阴性组，化疗后依据 Ki67表达改变情况阳转阴（A）组、阴转阳（B）组、阳不变（C）组和阴不变（D）组，随访5年，统计分析所有患者化疗疗效和生存情况。结果化疗前，阳性组患者化疗疗效明显优于阴性组，差异有统计学意义（p ＜0．05）；化疗后，在疗效方面，A 组＞C 组＞D 组＞B 组，差异有统计学意义（p ＜0．05）；在5年内生存率方面，A 组＞C 组＞D 组＞B 组，差异有统计学意义（p ＜0．05）。结论新辅助化疗可致使 TNBC 癌患者 Ki67的表达发生转变，有可能改善患者生存预后，值得临床作进一步研究。
목적：탐토신보조화료대삼음성유선암（Triple Negative Breast Cancer，TNBC）환자핵항원Ki67적영향。방법선취2012년6월～2014년3월기간아원신보조화료치료적 TNBC 환자136례，의거병채용면역조화법검측소유환자유선암조직중 Ki67표체정황，화료전분위양성조화음성조，화료후의거 Ki67표체개변정황양전음（A）조、음전양（B）조、양불변（C）조화음불변（D）조，수방5년，통계분석소유환자화료료효화생존정황。결과화료전，양성조환자화료료효명현우우음성조，차이유통계학의의（p ＜0．05）；화료후，재료효방면，A 조＞C 조＞D 조＞B 조，차이유통계학의의（p ＜0．05）；재5년내생존솔방면，A 조＞C 조＞D 조＞B 조，차이유통계학의의（p ＜0．05）。결론신보조화료가치사 TNBC 암환자 Ki67적표체발생전변，유가능개선환자생존예후，치득림상작진일보연구。
Objective To discuss the influence of neoadjuvant chemotherapy for Triple Negative Breast Cancer(TNBC) in patients with Ki67 nuclear antigens.Methods 136 patients with TNBC were selected from June 2012 to March 2014 in our Hospitals, and on the basis, immunohistochemical method was used to detect all patients Ki67 expression in breast cancer tissue .The patients were divided into positive group and negative group before chem -otherapy, and on the basis of Ki67 expression changes after chemotherapy and they were divided into yang to yin (A) group, yin to yang(B) group, Yang invariant(C) group and Yin invariant (D) group.Followed up for 5 years, all patients of chemotherapy efficacy and survival were analysed .Results Before chemotherapy, positive group chemo-therapy curative effect was better than negative group , and the difference was statistically significant (p <0.05); After chemotherapy, in the aspect of effect, A group >C group >D group >Bgroup(p <0.05); After chemotherapy, in the aspect of curative effect, A group >C group >D group >Bgroup(p <0.05).Conclusion Neoadjuvant chemo-therapy can change the patients with TNBC cancer Ki 67 positive expression, and it possible to improve the prognosis of patients survival, which is worth for further clinical research .